aTyr Pharma Inc

LIFE
1,59
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 13:00:00
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
01/4/202414:00GLOBEaTyr Pharma to Participate in April Investor Conferences
14/3/202421:00GLOBEaTyr Pharma Announces Fourth Quarter and Full Year 2023..
28/2/202414:00GLOBEaTyr Pharma to Webcast Conference Call Reporting Fourth..
21/2/202414:00GLOBEaTyr Pharma Announces Expanded Access Program (EAP) for..
07/2/202402:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202402:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202414:00GLOBEaTyr Pharma to Present Posters Highlighting Importance of..
18/1/202414:00GLOBEaTyr Pharma Announces Howard University President Emeritus..
10/1/202401:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202401:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202418:21EDGAR2Form SC 13G - Statement of acquisition of beneficial..
13/12/202300:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
13/11/202322:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202314:00GLOBEaTyr Pharma Presents Poster Demonstrating Preclinical..
09/11/202323:01EDGAR2Form S-3 - Registration statement under Securities Act of..
09/11/202322:42EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
09/11/202322:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202322:06EDGAR2Form 8-K - Current report
09/11/202322:00GLOBEaTyr Pharma Announces Third Quarter 2023 Results and..
01/11/202313:00GLOBEaTyr Pharma to Present at November Investor Conferences
31/10/202313:00GLOBEaTyr Pharma Announces Dosing of First Patient in Phase 2..
26/9/202315:01EDGAR2Form 8-K - Current report
11/9/202314:04EDGAR2Form 8-K - Current report
11/9/202314:00GLOBEaTyr Pharma Presents Efzofitimod Data Demonstrating..
24/8/202314:00GLOBEaTyr Pharma to Present at the H.C. Wainwright 25th Annual..
10/8/202322:07EDGAR2Form S-8 - Securities to be offered to employees in employee..
09/8/202322:14EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202322:10EDGAR2Form 8-K - Current report
09/8/202322:00GLOBEaTyr Pharma Announces Second Quarter 2023 Results and..
01/8/202322:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/6/202314:00GLOBEEuropean Commission Grants Orphan Drug Designation for aTyr..
20/6/202314:00GLOBEaTyr Pharma to Present on Lead Therapeutic Candidate..
09/6/202322:00GLOBEaTyr Pharma Announces Inducement Grants Under Nasdaq Listing..
06/6/202314:00GLOBEaTyr Pharma to Highlight Advancements in tRNA Synthetase..
25/5/202314:00GLOBEaTyr Pharma to Present at the 2023 Jefferies Healthcare..
22/5/202314:00GLOBEaTyr Pharma Presents New Data on Efzofitimod Mechanism of..
11/5/202322:00GLOBEaTyr Pharma to Present at the 2023 RBC Capital Markets..
09/5/202322:00GLOBEaTyr Pharma Announces First Quarter 2023 Results and..
Apertura: Min: Max:
Chiusura: 1,59

La tua Cronologia

Delayed Upgrade Clock

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network